Economy

Aimmune Therapeutics, Inc. (AIMT) Hits New 1-Year High on Analyst Upgrade

Several research analysts have recently issued reports on AIMT shares. With that said, researchers took a deep dive into the hotly debated question: is it too late to buy Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc. (AIMT) shares are up 27.18% for the week and that has got investors and traders sitting up and taking note. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a "buy" rating in a report on Thursday, July 27th.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Aimmune Therapeutics presently has an average rating of "Hold" and an average target price of $51.00.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT)'s stock has performed at 25.48%. Following the transaction, the insider now directly owns 25,000 shares in the company, valued at $420,000. These analysts have also projected a Low Estimate of $-0.76/share and a High Estimate of $-0.69/share. Aimmune Therapeutics, Inc. The company's market capitalization is $1.66 billion. AIMT's latest closing price was 58.70% away from the average price of 200 days while it maintained a distance of 42.95% from the 50 Day Moving Average and 29.61% away compared to its SMA 20.

Analysts expect Aimmune Therapeutics Inc (NASDAQ:AIMT) to report $-0.72 EPS on November, 13.They anticipate $0.19 EPS change or 35.85 % from last quarter's $-0.53 EPS.

As of the last earnings report the EPS was $-2.25 and is estimated to be $-2.71 for the current year with 50,535,000 shares outstanding.

What Historical Figures Say About Aimmune Therapeutics, Inc. The company was initiated on Monday, August 31 by Credit Suisse.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. President and CEO Stephen George Dilly sold 98,846 shares at a price of $26.26 on Friday the 6th.

About 2.72M shares traded or 649.83% up from the average. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The stock is also considered overbought with an RSI (14) now at 86.18. The shares were purchased at an average price of $26.24. Following the completion of the transaction, the insider now owns 20,000 shares of the company's stock, valued at $500,000. The disclosure for this sale can be found here. The company trades on average around 27024000 shares per market session. Corporate insiders own 24.56% of the company's stock. After $0.10 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 40.00% EPS growth. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company's stock valued at $1,892,000 after purchasing an additional 4,788 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Aimmune Therapeutics during the third quarter valued at $133,000. State Street Corp now owns 1,087,320 shares of the biotechnology company's stock worth $22,351,000 after purchasing an additional 228,429 shares in the last quarter.

As of quarter end Point72 Asset Management, L.p. had bought 314,259 shares growing its stake by 46.1%. Eagle Asset Management Inc. lifted its position in shares of Aimmune Therapeutics by 6.3% in the 2nd quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company's stock worth $4,675,000 after purchasing an additional 132,603 shares during the period.

Aimmune Therapeutics, Inc.is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system created to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.



Like this

Latest


25 October 2017
Asin and Rahul Sharma ecstatic as they welcome 'angelic' baby girl
In an official statment the couple said, "We are ecstatic to announce the arrival of our angelic baby girl earlier today". Actress Asin Thottumkal , known mononymously as Asin entered wedlock with business icon Rahul Sharma past year .

25 October 2017
Storm damages reported in North Carolina storm
Authorities in Watauga and McDowell counties reported completing water rescues as heavy rains caused flash floods in some areas. In South Carolina, tractor trailers were flipped, homes damaged and trees downed by a possible tornado in the Spartanburg area.

25 October 2017
Align Technology, Inc. (ALGN) Ownership Decreased by Robeco Institutional Asset Management Bv
On average, analysts expect Align Technology to post $3.41 EPS for the current fiscal year and $4.09 EPS for the next fiscal year. Align Technology's revenue was up 32.3% compared to the same quarter past year . ( NASDAQ ALGN ) opened at 202.76 on Tuesday.

25 October 2017
Cross-country woman biker Sana Iqbal dies in auto accident in Hyderabad
Although the cause of the accident is still not known at this point of time, it is claimed Sana was declared dead at the hospital. An email sent by Sana Iqbal to her friends detailing how she was being tortured by her husband has gone viral after her death.

25 October 2017
Analysts Review: Precision Drilling Corp (PDS)
Analysts are also projecting an Average Revenue Estimate for Precision Drilling Corporation as $261900 in the Current Quarter. Dimensional Fund Advisors LP grew its stake in shares of Precision Drilling Corporation by 0.4% during the first quarter.

25 October 2017
Pa. unemployment rate ticks down
The Mahoning Valley's nonseasonally adjusted unemployment rate was 7.2 percent during September, up 1 percent from last September. In May, Linn County's unemployment dipped to 4.1 percent, the lowest mark since OR began tracking county-by-county data in 1990.

25 October 2017
Warriors' Stephen Curry consoles Mavericks guard's grieving nephew
After the game, Curry told reporters what he said to the grieving child. The Warriors beat the Mavs 133-103 , as Curry scored 29 points.

25 October 2017
Cash crunch slowed Puerto Rico's appeal for grid help, CEO says
Besides monetary connections, Whitefish Energy also has direct political connections with some of Trump's cabinet secretaries. But some on Capitol Hill are concerned that Whitefish may have stood out for another reason.

25 October 2017
Pence breaks tie as Senate votes to repeal banking rule
The petition was organized by Public Citizen, Americans for Financial Reform, Consumers Union and several other consumer groups. They said consumers would still have the option to use arbitration to resolve a dispute, if both parties want to go that route.

25 October 2017
Star cricketer denies exposing himself to therapist
Gayle asked her: "What are you looking for?" the court heard, according to the Herald. "I remember being upset", Russell said. The next day, on 12 February, Russell said she got the bus to the SCG and set up the massage table and waited outside.



Recommended